{"filing":{"accession_number":"0001104659-26-078839","cik":"0000786947","ticker":null,"company_name":"ACURA PHARMACEUTICALS, INC","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"tm2619325d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926078839/tm2619325d1_8k.htm"},"events":[{"id":14646,"run_id":13048,"accession_number":"0001104659-26-078839","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.8,"summary":"Acura received three new loans totaling $400,000 from AD Pharma (May–June 2026) under an amended secured promissory note, bringing aggregate principal to $10.7 million as of June 24, 2026, with maturity extended to December 31, 2026. The company disclosed acute financial distress, stating that without additional financing by late July 2026, it will be forced to furlough/lay off employees, terminate operations, or seek bankruptcy protection.","company_name":"ACURA PHARMACEUTICALS, INC","ticker":null,"filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12132,"accession_number":"0001104659-26-078839","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses receipt of three new loans ($100,000 on May 15, $100,000 on May 29, and $200,000 on June 24, 2026) from AD Pharma, bringing the total principal balance to $10.7 million under an amended secured promissory note. While technically amendments to an existing credit facility rather than a wholly new debt issuance, the material substance is the creation of new direct financial obligations. The disclosure is material because the company explicitly states that without additional financing by late July 2026, it will be forced to furlough/lay off employees, terminate operations, or seek bankruptcy protection—indicating acute financial distress and going-concern risk tied directly to this debt arrangement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:17:17.199768+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12138,"accession_number":"0001104659-26-078839","item_number":"2.03","item_title":"Creation of a Direct Financial","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses amendments to a secured promissory note with Abuse Deterrent Pharma, LLC, extending the maturity date to December 31, 2026, and documenting continued loan advances (Loans #51–#62 totaling $1.3 million as of June 24, 2026, bringing aggregate principal to $10.694 million). This represents ongoing creation and modification of direct financial obligations under Item 2.03. While the note itself originated earlier, the amendments and continued advances constitute material modifications to the company's debt structure and financing arrangements that a reasonable investor would need to assess liquidity and solvency risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:17:17.199768+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12132,"accession_number":"0001104659-26-078839","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses receipt of three new loans ($100,000 on May 15, $100,000 on May 29, and $200,000 on June 24, 2026) from AD Pharma, bringing the total principal balance to $10.7 million under an amended secured promissory note. While technically amendments to an existing credit facility rather than a wholly new debt issuance, the material substance is the creation of new direct financial obligations. The disclosure is material because the company explicitly states that without additional financing by late July 2026, it will be forced to furlough/lay off employees, terminate operations, or seek bankruptcy protection—indicating acute financial distress and going-concern risk tied directly to this debt arrangement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:17:17.199768+00:00","company_name":"ACURA PHARMACEUTICALS, INC","ticker":null,"filing_date":"2026-06-29"},{"id":12137,"accession_number":"0001104659-26-078839","item_number":"2.01","item_title":"Completion of Acquisition","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The Item 2.01 caption references \"Completion of Acquisition or Disposition of Assets,\" but the exhibits reveal this is actually a series of amendments to an existing loan and license agreement with Abuse Deterrent Pharma, LLC, not a discrete acquisition or disposition event. The exhibits show: (1) an amended loan schedule reflecting cumulative borrowings of $10.7M as of June 24, 2026; (2) Amendment #14 to a License, Development and Commercialization Agreement extending the LIMITx™ regulatory submission timeline to December 31, 2026; (3) Amendment #8 to a secured promissory note extending the maturity date to December 31, 2026; and (4) Amendment #6 to a warrant extending its expiration to December 31, 2026. These are refinancing and timeline adjustments to an ongoing relationship, not a completed acquisition or asset disposition. The material financial obligation (the $10.7M loan) and the regulatory timeline extension warrant disclosure, but the event is best classified as a financial restructuring rather than M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:17:17.199768+00:00","company_name":"ACURA PHARMACEUTICALS, INC","ticker":null,"filing_date":"2026-06-29"},{"id":12138,"accession_number":"0001104659-26-078839","item_number":"2.03","item_title":"Creation of a Direct Financial","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses amendments to a secured promissory note with Abuse Deterrent Pharma, LLC, extending the maturity date to December 31, 2026, and documenting continued loan advances (Loans #51–#62 totaling $1.3 million as of June 24, 2026, bringing aggregate principal to $10.694 million). This represents ongoing creation and modification of direct financial obligations under Item 2.03. While the note itself originated earlier, the amendments and continued advances constitute material modifications to the company's debt structure and financing arrangements that a reasonable investor would need to assess liquidity and solvency risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:17:17.199768+00:00","company_name":"ACURA PHARMACEUTICALS, INC","ticker":null,"filing_date":"2026-06-29"}]}